Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer
February 17, 2022 08:30 ET
|
Celsion Corporation
OVATION 2 Study is Over 75% Enrolled; Full Enrollment Expected by Mid-2022 Novel Gene-Mediated Immunotherapy is Safe and Demonstrates an Acceptable Risk/Benefit When Administered Over...
Celsion Corporation Invited to Present Poster at Cytokine-Based Cancer Immunotherapies Summit
November 29, 2021 08:30 ET
|
Celsion CORP
Celsion Corporation’s GEN-1 IL-12 Program in Advanced Ovarian Cancer to be Featured in Poster Presentation Chief Science Officer Dr. Khursheed Anwer to Present and Participate in Two Panel...
Celsion Corporation Announces Oral Presentation at International Vaccines Congress
October 12, 2021 09:00 ET
|
Celsion CORP
Chief Science Officer Dr. Khursheed Anwer to Deliver Virtual Presentation on Celsion’s Ongoing Work with DNA-based Vaccines LAWRENCEVILLE, N.J., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Celsion...
Celsion Reports Data Safety Monitoring Board Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer
July 19, 2021 08:00 ET
|
Celsion CORP
OVATION 2 Study is 50% Enrolled; Excellent R0 Surgical Resection Noted Novel Gene-Mediated Immunotherapy is Safe and Demonstrates an Acceptable Risk/Benefit When Administered Over a Six-Month...
Celsion Corporation Expands Vaccine Advisory Board with the Addition of Dr. Dan H. Barouch and Dr. Luke D. Handke
July 15, 2021 08:00 ET
|
Celsion CORP
VAB member experience with vaccine research and immunology will guide development of the PLACCINE platform for the prevention and treatment of infectious agents, including SARS-CoV-2 ...
Celsion Corporation Establishes Wholly Owned Subsidiary to Manage Investigator-Sponsored Development of ThermoDox®
June 23, 2021 08:00 ET
|
Celsion CORP
Celsion GmbH will manage current and future cancer studies with ThermoDox® Celsion continues its strategic focus on the development of GEN-1 and PLACCINE LAWRENCEVILLE, N.J., June 23, 2021 ...
Celsion Corporation Appoints Dr. Stacy R. Lindborg to its Board of Directors
June 08, 2021 08:00 ET
|
Celsion CORP
25-year pharmaceutical industry executive brings broad drug development perspective Replaces Alberto Martinez, MD LAWRENCEVILLE, N.J., June 08, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation...
CELSION CORPORATION ANNOUNCES ADJOURNMENT OF ANNUAL MEETING
June 07, 2021 17:00 ET
|
Celsion CORP
A Quorum Has Been Achieved to Reconvene Annual Meeting on Thursday June 10, 2021 Polls Remain Open, Shareholders are Urged to Vote LAWRENCEVILLE, N.J., June 07, 2021 (GLOBE NEWSWIRE) -- Celsion...
Celsion Corporation Urges All Shareholders to Vote at the 2021 Annual Meeting to be Held on Friday June 4, 2021
June 02, 2021 08:00 ET
|
Celsion CORP
Calls for All Shareholders to Vote so Quorum Requirement to Hold The Meeting is Met LAWRENCEVILLE, N.J., June 02, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage...
Celsion Receives $1.85 Million from the Sale of its New Jersey State Net Operating Losses
May 11, 2021 08:00 ET
|
Celsion CORP
Non-Dilutive Funding Strengthens Balance Sheet, Extends Cash Runway Beyond 2024 Sale of an Additional $5.0 Million of State NOLs Expected in Future Years LAWRENCEVILLE, N.J., May 11, 2021 ...